Combination therapy targeting hypoxia inducible factor-α ( HIF-1 α) and Tissue Factor (TF) by the mTOR inhibitor Rapamycin and the histone deacetylase inhibitor LBH589

被引：0
|
作者：
Verheul, Henk M. W.
Qian, David Z.
Van Erp, Karen
Salumbides, Brenda
Sanni, Tolib
Atadja, Peter
Pili, Roberto
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Novartis Inst Biomed Res, E Hanover, NJ USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1033
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PX-478, a potent inhibitor of hypoxia-inducible factor-1 (HIF-1) and antitumor agent
    Welsh, SJ
    Williams, RR
    Kirkpatrick, DL
    Powis, G
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S90 - S90
  • [22] Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
    Falchook, Gerald S.
    Wheler, Jennifer J.
    Naing, Aung
    Jackson, Edward F.
    Janku, Filip
    Hong, David
    Ng, Chaan S.
    Tannir, Nizar M.
    Lawhorn, Kristie N.
    Huang, Mei
    Angelo, Laura S.
    Vishwamitra, Deeksha
    Hess, Kenneth
    Howard, Adrienne N.
    Parkhurst, Kristin L.
    Amin, Hesham M.
    Kurzrock, Razelle
    ONCOTARGET, 2014, 5 (21) : 10280 - 10292
  • [23] Synergistic cytotoxic effects of a combination of a novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells.
    Scuto, A
    Annavarapu, S
    Bali, P
    McCullers, M
    Fiskus, W
    Mouttaki, A
    Guo, F
    Sigua, C
    Sondarva, G
    Atadja, P
    Manley, P
    Bhalla, KN
    BLOOD, 2004, 104 (11) : 546A - 546A
  • [24] Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization
    Tauser, Roxana-Georgiana
    Zugun-Eloae, Florin
    Jitaru, Daniela
    Carasevici, Eugen
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2009, 16 (03): : 7 - 12
  • [25] Pharmacokinetic Characterization of LW6, a Novel Hypoxia-Inducible Factor-1α (HIF-1α) Inhibitor in Mice
    Lee, Ji-Yoon
    Lee, Kiho
    Lee, Kyeong
    Kang, Jong Soon
    Kim, Min Ju
    Yoo, Dong Gu
    Kim, Jung Ah
    Shin, Eun Jin
    Oh, Soo Jin
    MOLECULES, 2021, 26 (08):
  • [26] Targeting topoisomerases to inhibit hypoxia inducible factor 1 (HIF-1): Mechanism and clinical implications.
    Melillo, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9174S - 9175S
  • [27] Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1α suppression
    Kim, Se-Hee
    Kim, Kyu-Won
    Jeong, Joo-Won
    ONCOLOGY REPORTS, 2007, 17 (04) : 793 - 797
  • [28] Gene expression screening for hypoxia inducible factor-1 (HIF-1) and nuclear factor-κB in human cDNA libraries
    Bermudez, V
    Lukiw, WJ
    Bazan, NG
    JOURNAL OF NEUROCHEMISTRY, 2001, 78 : 169 - 169
  • [29] Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)
    Zang, Hongjing
    Qian, Guoqing
    Zong, Dan
    Fan, Songqing
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    CANCER, 2020, 126 (09) : 2024 - 2033
  • [30] Role of hypoxia-inducible-factor-1α (HIF-1α) in ferroptosis of adipose tissue during ketosis
    Fan, Yunhui
    Ma, Li
    Fang, Xinxin
    Du, Shuyu
    Mauck, John
    Loor, Juan J.
    Sun, Xudong
    Jia, Hongdou
    Xu, Chuang
    Xu, Qiushi
    JOURNAL OF DAIRY SCIENCE, 2024, 107 (12) : 10611 - 10627
12345